Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CHF 1.05B
- Enterprise Value Operating value: market cap + total debt − cash.
- CHF 928.40M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CHF 182.27M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CHF 134.49M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CHF 80.45M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CHF 11.19
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 3.35
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.93%
- Shares Outstanding
- 15.94M
- Float Shares
- 8.44M
- Implied Shares Outstanding
- 15.94M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-2.73%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
44.14%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
73.79%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
32.91%
- ROA Return on assets: net income ÷ total assets.
-
6.88%
- ROE Return on equity: net income ÷ shareholder equity.
-
12.34%
- Revenue Growth Year-over-year revenue growth.
-
-62.00%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
10.92%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.59
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.58
- Total Cash Cash and equivalents.
- CHF 126.62M
- Total Debt Short + long-term interest-bearing debt.
- CHF 2.70M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CHF -123.93M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.03
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CHF 73.50M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CHF 51.49M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
40.33%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
28.25%
- Cash Conversion (OpCF/EBITDA)
- 0.91
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.